Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 13, 2024, serves as a transaction notification for the month of March 2024. The document discloses insider trading activities involving Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company. It does not contain financial performance results, operational updates, or strategic commentary.
Key Financial Metrics
The filing text does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transaction prices and volumes for individual executives.
Material Changes and Transaction Details
The filing reports multiple transactions executed on the London Stock Exchange (XLON) between March 11 and March 12, 2024. These include both sales of existing holdings and acquisitions under the Company's Share Reward Plan.
- Sales Transactions:
- Sally Jackson (SVP, Global Communications & CEO Office): Sold 9,000 shares at £16.7189 and 4,340 shares at £16.7944 on March 11.
- Dylan Jackson (PCA of Sally Jackson): Sold 13,616 shares at £16.6871 on March 11 and 2,476 shares at £16.7145 on March 12.
- Deborah Waterhouse (CEO, ViiV Healthcare): Sold 60,000 shares at £16.8004 on March 12.
- Acquisitions (Share Reward Plan):
- Emma Walmsley (CEO): Acquired 14 shares (7 partnership, 7 matching) at £16.6610 on March 11.
- Julie Brown (CFO): Acquired 16 shares (8 partnership, 8 matching) at £16.6610 on March 11.
- James Ford (SVP, Group General Counsel): Acquired 16 shares (8 partnership, 8 matching) at £16.6610 on March 11.
- Sally Jackson (SVP, Global Communications): Acquired 14 shares (7 partnership, 7 matching) at £16.6610 on March 11.
- David Redfern (President, Corporate Development): Acquired 16 shares (8 partnership, 8 matching) at £16.6610 on March 11.
- Regis Simard (President, Global Supply Chain): Acquired 16 shares (8 partnership, 8 matching) at £16.6610 on March 11.
- Philip Thomson (President, Global Affairs): Acquired 16 shares (8 partnership, 8 matching) at £16.6610 on March 11.
- Deborah Waterhouse (CEO, ViiV Healthcare): Acquired 14 shares (7 partnership, 7 matching) at £16.6610 on March 11.
- Victoria Whyte (Company Secretary): Acquired 14 shares (7 partnership, 7 matching) at £16.6610 on March 11.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of share transactions.
Investor Verification Checklist
- Verify the total number of shares sold by Deborah Waterhouse (60,000) against her total holdings to assess the significance of the reduction.
- Confirm the aggregate volume of sales by Sally Jackson and Dylan Jackson (17,436 shares combined) relative to their respective positions.
- Review the company's Share Reward Plan terms to understand the vesting conditions for the small acquisitions made by the executive team.
- Check the prevailing market price of GSK ordinary shares on March 11-12, 2024, to confirm the transaction prices were at fair market value.